Memantine Mylan

Selected form

Memantine Hydrochloride

Method of action: Psychoanaleptics

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Memantine Mylan

Property	Description
Active ingredient	Memantine Hydrochloride
Form	Film-coated tablets; Oral solution
Pharmacological class	N-methyl-D-aspartate (NMDA) receptor antagonist
General purpose	Support for cognitive processes
Origin	Synthetic compound

What Type of Medicine is Memantine Mylan?

Memantine Mylan is a prescription-only medicine containing the active substance Memantine Hydrochloride, formally classified as an N-methyl-D-aspartate (NMDA) receptor antagonist. This drug belongs to a specialized pharmacological class of anti-dementia agents and is a synthetic compound, not derived from natural sources. The classification as an NMDA receptor antagonist confirms its targeted action in the central nervous system, where it works to stabilize nerve signaling. Clinical practice and pharmacological studies support Memantine's role in this therapeutic area. As a therapeutic agent, memantine is used to improve memory, awareness, and the ability to function, focusing on helping patients maintain their mental abilities and daily function.

Composition and Available Forms of Memantine Mylan

The core composition features Memantine Hydrochloride alongside the requisite pharmaceutical excipients necessary for manufacturing stability and delivery. The drug is supplied by the Mylan brand and is formulated for oral administration, ensuring the drug enters the systemic circulation for its intended action. It is available in multiple pharmaceutical preparations, including film-coated tablets and an oral solution. The availability of both forms provides flexible administration options, especially for the elderly population with potential swallowing difficulties.

General Purpose and High-Level Action

The high-level therapeutic purpose of this medication is to support the preservation and maintenance of cognitive processes. Memantine achieves this by engaging in the modulation of glutamatergic neurotransmission. It acts as a selective blocker, preventing the chronic, pathological overstimulation of nerve receptors by the excitatory neurotransmitter glutamate, a process that is often associated with nerve cell damage. By stabilizing these nerve signals, the drug aims to provide a neuroprotective effect, supporting the function of brain cells involved in memory and learning.

Regulatory References

What side effects are possible with Memantine Mylan?

Possible Side Effects and Safety Information

The safety profile of Memantine Hydrochloride is officially documented based on standard regulatory classifications, grouping potential adverse reactions by frequency and the body's System-Organ Classes (SOCs), such as Nervous System Disorders, Gastrointestinal Disorders, and Vascular Disorders.

Adverse Reactions Classified by Frequency

Adverse events are categorized according to their reported frequency in official prescribing information:

Common (1 in 100 to 1 in 10 users): Dizziness, Headache, Constipation, Somnolence (Drowsiness), Hypertension, Vomiting, Dyspnoea (shortness of breath), and Drug Hypersensitivity.
Uncommon (1 in 1,000 to 1 in 100 users): Confusion, Hallucinations, Fatigue, Fungal infections, Cardiac failure, and Venous thromboembolism (VTE).
Very Rare: Convulsions.
Frequency Not Known: Serious reactions documented in post-marketing surveillance, including Psychotic reactions, Pancreatitis, and Hepatitis.

Safety Considerations and Restrictions

Official labeling defines specific constraints for use. The medicine is contraindicated in individuals with a known hypersensitivity to Memantine Hydrochloride or any non-active ingredients. Caution is advised in patients with pre-existing conditions, particularly those with severe renal impairment and severe hepatic impairment. The use of Memantine alongside other N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, is generally restricted due to the potential for enhanced central nervous system (CNS)-related adverse reactions.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information

Overdose scope

Documented overdose presentations: Manifestations documented in regulatory sources include Central Nervous System (CNS) symptoms such as confusion, somnolence, agitation, stupor, and hallucinations, along with Gastrointestinal (GI) effects like vomiting and diarrhea.

Physiological systems affected (as stated in label): CNS, GI system, and potentially the Cardiovascular system (e.g., hypertension, tachycardia) in extreme reported cases.

Dose-related or exposure-related factors (if applicable): Reported overdose incidents range from doses with minimal symptoms to extreme cases involving coma and proconvulsive states.

Population-specific overdose notes (if applicable): Conditions that make the urine alkaline may reduce memantine's elimination, potentially leading to drug accumulation and an increased risk of adverse effects.

Emergency-response statements (as written in official documents): Treatment in the event of an overdose is primarily symptomatic, as no specific antidote is available.

When immediate medical help is required (label-derived phrasing only): Contact a doctor or poison control center immediately following a suspected overdose. Close monitoring is required, particularly for severe CNS overstimulation.

Overdose classifications (high-level)

Severity classification (as defined in official documents): The spectrum of reported outcomes ranges from minimal symptoms to severe, life-threatening CNS effects, including coma.

Regulatory basis (EMA / FDA / etc.): This information is based on the Summary of Product Characteristics (SmPC) and FDA Prescribing Information.

Overdose-context constraints (as defined in official documents): Only limited experience with overdose is available from clinical studies and post-marketing data.

Resulting overdose structure

Official overdose statements:

No specific antidote for memantine is available; management must be symptomatic.
Severe outcomes reported include coma and proconvulsive state.
Standard measures such as gastric lavage and the use of activated charcoal are listed as appropriate procedures.
Patients must contact a doctor or poison control center immediately.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by listing specific CNS and systemic manifestations, highlighting the clinical severity that necessitates immediate medical attention. The documented lack of a specific antidote dictates that the official management approach focuses exclusively on supportive and symptomatic care.

Therapeutic Uses of Memantine Mylan

Quick Facts

Main Use: Addresses symptoms of Alzheimer's dementia.
Therapeutic Focus: Assists in managing moderate to severe stages of the condition.
Potential Benefit: May support cognitive function and daily activity management.

Memantine Mylan is a prescription medication utilized in the management of moderate to severe Alzheimer’s disease. This is a progressive brain disorder that primarily impacts memory, intellectual capacity, and behavior. The drug is intended to help reduce the non-motor symptoms associated with the condition and may contribute to a modest improvement in cognitive function and the ability to manage routine daily activities.

It is important to understand that this treatment does not represent a cure for Alzheimer’s disease and is not expected to prevent the progression of the underlying condition. Its purpose is to assist in symptom management for individuals who have been diagnosed with the moderate to severe form of the disorder. Treatment should be initiated and regularly monitored by a medical professional experienced in the diagnosis and care of Alzheimer’s disease.

Eligibility and Restrictions for Use

Official Population Eligibility and Restrictions

Memantine Mylan is officially indicated for use in adult patients diagnosed with moderate to severe Alzheimer's disease. The regulatory eligibility profile is defined by clear boundaries related to hypersensitivity, age, organ function, and reproductive status.

Absolute Contraindication

The medicine is strictly contraindicated in any patient who has a known hypersensitivity to memantine hydrochloride or to any of the excipients used in the tablet formulation.

Restricted and Non-Recommended Use

Use is not recommended for two key groups: children and adolescents under 18 years due to insufficient data on safety and efficacy, and patients with severe hepatic impairment (liver function impairment).

For individuals with severe renal impairment (kidney function impairment), the medicine is permitted but restricted to a lower maintenance dose, necessitated by the drug’s slower clearance. Close supervision is also required for patients with epilepsy or those with conditions that may affect urine pH.

Pregnancy and Lactation Status

Memantine Mylan should not be used during pregnancy unless clearly necessary. Furthermore, women taking the medicine should not breast-feed, as the drug is likely excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Memantine Mylan primarily defines interactions based on pharmacokinetics (how the body handles the drug) and pharmacodynamics (how the drug affects the body).

Interactions Requiring Avoidance

Co-administration with other N-methyl-D-aspartate (NMDA) antagonists should be avoided. This includes agents such as amantadine, ketamine, and dextromethorphan. This restriction is due to the potential for an enhanced risk of central nervous system (CNS)-related adverse reactions.

Pharmacokinetic Clearance Interactions

Memantine Mylan is partially eliminated through the renal cationic transport system. Substances that share this system, such as cimetidine, ranitidine, and quinidine, may compete for clearance, potentially increasing memantine plasma levels. Additionally, any drug or severe dietary change that causes urine alkalinisation (e.g., carbonic anhydrase inhibitors) will significantly decrease memantine’s urinary elimination, which raises the potential for drug accumulation. Specific clinical conditions, such as Renal Tubular Acidosis, also require careful monitoring for this reason.

Other Documented Interactions

The effects of L-dopa, dopaminergic agonists, and anticholinergic agents may be enhanced.
The co-administration may reduce the bioavailability of co-administered hydrochlorothiazide by 20%.
Memantine does not inhibit or induce major CYP450 enzymes; therefore, pharmacokinetic interaction with drugs metabolized by this system is not expected.
The effects of barbiturates and neuroleptics may be reduced.

Mechanism of Action

Memantine Mylan functions as a low-to-moderate affinity, uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a glutamate-gated ion channel located in the central nervous system.

The molecule enters the channel pore only when the receptor is already in its open, activated state. This use-dependent mechanism allows the drug to selectively block sustained, pathologically high activation of the receptor by elevated extracellular glutamate concentrations. By physically occupying a binding site within the cation channel, memantine sterically impedes the influx of extracellular calcium ions (Ca^2+) into the postsynaptic neuron.

This modulation of Ca^2+ influx is voltage-dependent and has fast unblocking kinetics, permitting the rapid disassociation of memantine during the brief, high-concentration synaptic glutamate release that mediates physiological neurotransmission. Consequently, the drug preferentially dampens the continuous, lower-level NMDA receptor current that contributes to intracellular Ca^2+ overload. The reduction in excessive intracellular Ca^2+ accumulation prevents the subsequent activation of destructive intracellular cascades and limits cellular dysfunction across neural networks.

Dosage and Administration Information

Official Administration Guidelines

Memantine Mylan, containing memantine hydrochloride, is administered orally and is available as film-coated tablets or an oral solution. The treatment plan is intended for long-term use and should be regularly reassessed by a physician, typically within three months of starting treatment.

Dosing Schedule and Frequency

The medicine is initiated at a starting dose of 5 mg once daily and is gradually increased over a minimum four-week period to reach the standard maintenance dose of 20 mg per day. The minimum recommended interval between dose increases is one week. The final 20 mg daily dose is generally administered as 10 mg taken twice daily.

Week	Daily Dose	Administration
1	5 mg	Once daily
2	10 mg	Once daily
3	15 mg	Divided doses
4 onwards	20 mg	10 mg twice daily

Procedural Use and Adjustments

Memantine Mylan may be taken with or without food and should be taken at the same time every day to maintain a consistent schedule. For patients with severe renal impairment (creatinine clearance 5 to 29 mL/min), the maximum total daily dose must be reduced to 10 mg. If a single dose is missed, patients should not double the next dose, but should take the subsequent dose as scheduled. Treatment that has been interrupted for several days may require resuming at a lower dose and following the standard re-titration scheme.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Memantine Mylan

Evidence for Use in Moderate to Severe Alzheimer's Disease

Research examining Memantine Mylan was primarily conducted in individuals diagnosed with moderate to severe Alzheimer's disease (AD). The research structure includes Randomized Controlled Trials (RCTs), where patients were observed over defined time intervals, alongside meta-analyses that combined data from numerous individual studies.

Researchers used validated scales to examine several key areas where symptoms may vary in intensity. Studies monitored cognitive function (such as memory and thinking skills), functional ability (reflecting daily activity level and independence), and the patient's overall clinical status. These studies were conducted during periods of increased symptom activity and often compared measured outcomes in patients taking Memantine Mylan to those receiving an inactive placebo.

Analysis of Short- and Intermediate-Term Trial Data

Studies conducted during short-term (around 12 weeks) and intermediate-term (up to 24 to 28 weeks) periods form the foundation of the evidence. Findings describe patterns observed in these studies across the measured domains of cognition, function, and behavior. Research highlights changes measured during the study period, and findings describe patterns observed in the measured outcomes for this specific population.

Long-Term Studies and Follow-Up

The clinical data used to support the medicine's authorization were gathered from the intermediate-term trials mentioned above. For long-term outcomes, high-certainty evidence is limited. Research has described the continuity of the measured change in those who switched from placebo to Memantine Mylan during extension phases. However, data for long-term outcomes and the durability of measured change are not fully established using the same high-certainty structure of prolonged, placebo-controlled trials.

What Remains Unclear or Under Research

One key limitation consistently documented in scientific reviews is that the measured differences in outcomes observed in the studies are generally described as being modest or small in size.

Furthermore, certainty remains low regarding the role of Memantine Mylan in mild AD, as research exploring short-term symptom changes in this group yielded inconsistent findings. Follow-up durations were limited in the core comparative studies, meaning that long-term effects are not fully established regarding the medicine's influence on the long-term progression of the condition.

Frequently Asked Questions (FAQ)

Common questions about Memantine Mylan (FAQ)

Q: Can I drink alcohol while taking Memantine Mylan?

Official information generally advises patients to discuss the use of this medicine with alcohol with their healthcare professional. The guidance reflects the potential for combined effects of the medicine and alcohol on the central nervous system, as noted in official sources.

Q: What should I do if the side effects of Memantine Mylan seem severe?

Official patient information lists specific serious, but uncommon or very rare, side effects, such as Cardiac failure or Convulsions. Official patient information indicates that severe or unusual reactions, such as those listed, are events for which medical attention may be necessary.

Q: How is Memantine Mylan different from other drugs used for the same condition?

Memantine Mylan is formally classified as an N-methyl-D-aspartate (NMDA) receptor antagonist. This mechanism involves regulating specific nerve signals in the brain. This targeted action is different from other primary classes of medicine used for the same condition, such as the cholinesterase inhibitors.

Q: What evidence exists regarding Memantine Mylan's ability to help with daily living activities?

Clinical trials monitored functional ability using standardized scales that measure independence in Activities of Daily Living (ADLs). Research findings describe measured changes in these functional domains for the studied population with moderate to severe Alzheimer’s disease.

Q: Why do official sources state that Memantine Mylan should be used with caution in certain patients?

Caution is specifically advised for patients with certain pre-existing conditions, particularly those that may affect the pH level of the urine. This caution is related to the drug’s elimination from the body, as changes in urine pH (acidity or alkalinity) can decrease the body's clearance of the medicine, which may lead to drug accumulation.

Q: How long after starting Memantine Mylan does a healthcare provider typically check for initial results?

Official guidelines state that treatment with Memantine Mylan is intended for long-term use and should be regularly reassessed by a physician. This re-evaluation is typically recommended to occur within three months of starting treatment.

Q: How quickly should someone expect to notice the effects of Memantine Mylan?

The medicine is started at a low amount and is gradually increased to the standard amount over several weeks. Since the dose is gradually increased over a minimum four-week period, the expected measurable changes may be observed gradually over that time frame and beyond.

Q: Do I need to take Memantine Mylan forever?

Memantine Mylan is indicated for long-term use in the treatment of moderate to severe Alzheimer's disease. However, the patient's need for continued treatment should always be regularly reassessed by their treating physician.

Q: What happens if I forget to take a dose of Memantine Mylan?

Regulatory documents state that if a single dose is missed, patients should take the next scheduled dose and are advised not to double up to make up for the missed one. If treatment has been interrupted for several days, the dose may need to be resumed at a lower amount and increased again gradually.

Q: Can Memantine Mylan cause insomnia or affect sleep?

The official product labeling lists somnolence (drowsiness) as the most common sleep-related side effect. Insomnia (difficulty falling or staying asleep) is not generally listed in the common or uncommon adverse events categories in the official product labeling.

Q: Are there any common foods or supplements that interact with Memantine Mylan?

Memantine Mylan may be taken with or without food. However, regulatory sources caution that certain drugs or severe dietary changes that cause urine alkalinisation (making urine less acidic) can significantly slow the body’s elimination of the drug, which may lead to drug accumulation.

Q: Is Memantine Mylan considered an antidepressant?

No. Memantine Mylan is formally classified as an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-dementia agent. It belongs to a specialized pharmacological class and is not classified as an antidepressant in official product labeling.

Q: Can someone stop taking Memantine Mylan suddenly?

Regulatory information defines the procedure for gradually increasing the dose and resuming treatment after an interruption of several days, indicating that treatment should not typically be stopped suddenly. This procedure should be discussed with a healthcare provider.

Q: Does Memantine Mylan work right away or does it take time?

The drug is started at a low amount and is gradually increased over a minimum four-week period to reach the full maintenance dose. This procedure indicates that the effects are not immediate and may take time to become noticeable.

Q: Is there a generic version of Memantine Mylan available?

The active substance in the medicine is memantine hydrochloride. Regulatory books confirm that generic versions of memantine are available on the market, manufactured by various pharmaceutical companies.

Q: Are there any long-term effects associated with Memantine Mylan use?

The primary clinical data used for authorization was gathered from intermediate-term trials lasting up to 28 weeks. Official documents state that high-certainty evidence regarding the long-term outcomes and durability of measured change is limited.

Q: Who is generally considered eligible to use Memantine Mylan?

The official indication specifies the medicine is for adult patients who have been diagnosed with moderate to severe Alzheimer's disease. The medicine is generally not recommended for children or adolescents due to insufficient data.

Q: Is Memantine Mylan known to interact with common pain relievers?

Regulatory warnings define interactions with several classes of drugs. This includes other NMDA antagonists like dextromethorphan (found in some cough/cold/pain medicines) and certain anticholinergic agents, whose effects may be altered by Memantine.

Q: Why is the drug given under the name 'Memantine Mylan'?

The name indicates both the active ingredient and the supplier. The active substance is memantine hydrochloride. The addition of 'Mylan' signifies that this particular preparation is produced and supplied by the pharmaceutical company Viatris (formerly Mylan).

Q: Does taking Memantine Mylan require any regular monitoring or blood tests?

Regulatory documents advise caution for patients with renal impairment. While the label does not mandate specific blood tests, routine health monitoring may be required.

Q: Are there any warnings about driving or operating machinery while on Memantine Mylan?

Yes. Official patient labeling states that the drug can cause side effects like dizziness and confusion. These effects may impair a person's ability to drive or operate complex machinery, and caution is advised.

Q: Are headaches a common initial side effect when starting Memantine Mylan?

According to the official safety profile, headache is listed as a common adverse reaction, meaning it has been reported in clinical studies in 1 in 100 to 1 in 10 users.

Q: How long does the effect of one dose of Memantine Mylan typically last?

Memantine has a relatively long terminal elimination half-life, ranging from approximately 60 to 80 hours. This long half-life contributes to the drug’s sustained presence in the body over time.

Q: Is it normal to feel more confused or restless when first starting the treatment?

Confusion is listed as an uncommon side effect (reported in 1 in 1,000 to 1 in 100 users). Official product information documents other central nervous system effects that patients may experience.

Q: Does Memantine Mylan interact with common heartburn medications?

Memantine’s clearance from the body can be affected by certain medicines often used for heartburn. Specifically, cimetidine and ranitidine may compete for the same transport system in the kidneys, potentially raising Memantine levels.

Q: Are there different strengths of Memantine Mylan available?

Yes, official prescribing information confirms that Memantine Mylan is available in multiple strengths for oral administration. This includes film-coated tablets in strengths of 5 mg and 10 mg.

Q: What general expectations should patients have about using Memantine Mylan long-term?

The drug is intended to support the maintenance of cognitive processes and functional ability. Clinical trials describe measured differences in outcomes that are generally considered modest or small in size.

How should Memantine Mylan be stored and disposed of?

Storage and Disposal: Official Regulatory Requirements

Labeled Storage Requirement	Official Regulatory Statement
Temperature and Environment	This medicinal product does not require any special storage conditions.
Child Safety	Keep this medicine out of the sight and reach of children.
Stability and Packaging	Do not use this medicine after the expiry date (EXP) stated on the carton and blister.

Memantine Mylan is stable at room temperature and has no explicit requirements for protection from light or moisture beyond storage in its original container. The mandatory constraint is focused on safety, requiring the medicine to be stored away from children.

Official Disposal Instructions

Unused or expired Memantine Mylan and waste materials must not be thrown away via wastewater or household waste. Patients are instructed to ask their pharmacist how to throw away medicines no longer used, as these measures are required to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.